ES2128322T3 - Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos. - Google Patents

Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos.

Info

Publication number
ES2128322T3
ES2128322T3 ES91915038T ES91915038T ES2128322T3 ES 2128322 T3 ES2128322 T3 ES 2128322T3 ES 91915038 T ES91915038 T ES 91915038T ES 91915038 T ES91915038 T ES 91915038T ES 2128322 T3 ES2128322 T3 ES 2128322T3
Authority
ES
Spain
Prior art keywords
peptides
procedures
human immunodeficiency
immunodeficiency viruses
infections due
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915038T
Other languages
English (en)
Inventor
Anders Vahlne
Bo Svennerholm
Lars Rymo
Stig Jeansson
Peter Horal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntello Vaccine Development AB
Original Assignee
Syntello Vaccine Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Vaccine Development AB filed Critical Syntello Vaccine Development AB
Application granted granted Critical
Publication of ES2128322T3 publication Critical patent/ES2128322T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE HA DESCUBIERTO QUE PEPTIDOS RELATIVAMENTE CORTOS TALES COMO LA GLICIL-PROLILIR DE FORMA EFECTIVA LAS INFECCIONES POR HIV DE LAS CELULAS Y LAS FORMACIONES CINCIATICAS ENTRE CELULAS INFECTADAS Y NO INFECTADAS POR EL HIV. LOS PEPTIDOS SON ADECUADOS PARA LA TERAPIA DE PACIENTES INFECTADAS CON EL HIV Y EN LA PREVENCION DE LAS INFECCIONES POR HIV.
ES91915038T 1990-08-22 1991-08-20 Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos. Expired - Lifetime ES2128322T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57108090A 1990-08-22 1990-08-22

Publications (1)

Publication Number Publication Date
ES2128322T3 true ES2128322T3 (es) 1999-05-16

Family

ID=24282265

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915038T Expired - Lifetime ES2128322T3 (es) 1990-08-22 1991-08-20 Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos.

Country Status (17)

Country Link
EP (1) EP0545991B1 (es)
JP (1) JP3115596B2 (es)
KR (1) KR100220531B1 (es)
AT (1) ATE173934T1 (es)
AU (1) AU667290B2 (es)
BR (1) BR9106772A (es)
CA (1) CA2088788C (es)
DE (1) DE69130571T2 (es)
DK (1) DK0545991T3 (es)
ES (1) ES2128322T3 (es)
FI (1) FI930519A (es)
GR (1) GR3029523T3 (es)
HU (1) HUT63177A (es)
MC (1) MC2306A1 (es)
NO (1) NO930401L (es)
OA (1) OA10051A (es)
WO (1) WO1992003147A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523157A (ja) * 2006-01-13 2009-06-18 オンコレー アーベー 虚血および神経変性の処置のための化合物
FR2925500B1 (fr) * 2007-12-21 2011-05-06 Vincience Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2925501B1 (fr) 2007-12-21 2012-12-14 Vincience Peptide activateur de la synthese des aquaporines et composition cosmetique et/ou pharmaceutique le contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108022T1 (de) * 1985-10-24 1994-07-15 Southwest Found Biomed Res Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.

Also Published As

Publication number Publication date
NO930401L (no) 1993-02-17
AU667290B2 (en) 1996-03-21
AU8433291A (en) 1992-03-17
FI930519A (fi) 1993-04-21
JPH06504035A (ja) 1994-05-12
ATE173934T1 (de) 1998-12-15
FI930519A0 (fi) 1993-02-05
GR3029523T3 (en) 1999-06-30
EP0545991B1 (en) 1998-12-02
JP3115596B2 (ja) 2000-12-11
CA2088788A1 (en) 1992-02-23
WO1992003147A1 (en) 1992-03-05
NO930401D0 (no) 1993-02-05
HU9300456D0 (en) 1993-05-28
EP0545991A1 (en) 1993-06-16
DE69130571D1 (de) 1999-01-14
HUT63177A (en) 1993-07-28
MC2306A1 (fr) 1993-09-27
DK0545991T3 (da) 1999-08-16
CA2088788C (en) 2003-12-16
KR100220531B1 (ko) 1999-10-01
DE69130571T2 (de) 1999-06-17
OA10051A (en) 1996-10-14
BR9106772A (pt) 1993-07-20

Similar Documents

Publication Publication Date Title
TR199903053T2 (xx) Benzimidazol t�revleri.
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
MY117892A (en) Therapeutic compounds
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
EP0616535A4 (en) PROCESS FOR THE TREATMENT OF VIRAL INFECTIONS.
ATE169822T1 (de) Behandlung von herpesvirus infektion
ES2128322T3 (es) Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos.
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
FI944561A0 (fi) HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV-infektion ehkäisemiseksi ja hoitamiseksi
ATE316789T1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
RU93005034A (ru) Пептиды, блокирующие инфекцию вируса иммунодефицита человека, способы их применения
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
EP0247873A3 (en) Bacteriocins and compositions thereof in anti-viral treatment
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 545991

Country of ref document: ES